REG - BioPharma Credit PLC - Statement re ARCHIMED

Biopharma CreditAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9090Ca&default-theme=true

RNS Number : 9090C  BioPharma Credit PLC  05 May 2026

5 May 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

STATEMENT RE ARCHIMED ACQUISITION OF ESPERION THERAPEUTICS, INC.

 

 

The Company notes the announcement released on 1 May 2026 by Esperion
Therapeutics, Inc. ("Esperion") regarding the entering into of a definitive
agreement under which funds managed by ARCHIMED, an investment firm focused
exclusively on healthcare industries ("ARCHIMED"), will acquire Esperion in a
transaction valued at up to approximately US$1.1 billion in total equity value
on a fully diluted basis, assuming full achievement of certain
commercial-based milestones (the "Acquisition").

 

In connection with the Acquisition, the Company, along with BioPharma Credit
Investments V (Master) LP, provided committed financing to ARCHIMED of up to
USD$400 million, subject to customary closing conditions for the
Acquisition.  The Company's allocation of such commitment will be between
USD$78 to 120 million.  Esperion expects the Acquisition to close in the
third quarter of 2026, subject to customary closing conditions, including
approval by Esperion's shareholders and receipt of certain required regulatory
approvals.  Since ARCHIMED is a privately held company, further details about
the senior secured loan facility are not publicly available, but the terms of
the loan are generally comparable with the Company's other investments.

 

 

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQUSOWRNUUVRAR



            Copyright 2019 Regulatory News Service, all rights reserved